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Studies have led to proposed reaction mechanisms for

SYNTHASES

isoprenoid production; see, e.g., Cane et al., 1985, Bioorg.
Chem., 13:246—265; Wheeler and Croteau, 1987, Proc. Natl.
Acad. Sci. USA, 84:4856—4859; and Pyun et al., 1994,Arch.

CROSS REFERENCE TO RELATED
APPLICATIONS

Biochem. Biophys., 308:488—496. The studies used sub

This application is a divisional of and claims priority
under 35 USC. §120 to US. application Ser. No. 09/398,
395, ?led Sep. 17, 1999, Which claims bene?t under 35 USC

§119(e) of US. Provisional Application No. 60/150,262,
?led Aug. 23, 1999, US. Provisional Application No.
60/130,628, ?led Apr. 22, 1999, and US. Provisional Appli
cation No. 60/100,993, ?led Sep. 18, 1998.

strate analogs and suicide inhibitors (Croteau, 1994, Arch.
Biochem. Biophys., 251:777—782; Cane et al., 1995,
Biochemistry, 34:2471—2479; and Croteau et al., 1993,
Arch. Biochem. Biophys., 307:397—404), as Well as
10

This Work Was supported, in part, With funding from NIH

(GM54029 and GM07240) and NSF (IBW-9408152).
Therefore, the Unites States Federal Government may have
certain rights in the invention.

15

success in de?ning the active site due to inherent limitations
SUMMARY OF THE INVENTION
20

have been characteriZed With tens to hundreds of neW
structures identi?ed each year. These molecules can ful?ll a

serve as pheromones, defensive agents, visual pigments,

The invention describes a method of identifying alpha
carbon atoms found in the active site of a terpene synthase
and describes these atoms in three-dimensional space as Well

variety of roles. For example, monoterpenes can be used as

fragrances and ?avors. Sesquiterpenes and diterpenes can

al., 1992, Arch. Biochem. Biophys., 296:49—57; and Raja
onarivony et al., 1992, Arch. Biochem. Biophys.,
299:77—82). HoWever, these studies have resulted in limited
With these techniques.

BACKGROUND OF THE INVENTION

Isoprenoid compounds are organic molecules produced
by a Wide range of organisms (e.g., plants, bacteria, fungi,
etc). To date, over 23,000 individual isoprenoid molecules

chemical-modifying reagents and site-directed mutagenesis
in efforts to identify amino acids essential for catalysis (Cane
et al., 1995, Biochemistry, 34:2480—2488; Rajaonarivony et

25

as the spatial relationships among them. The present inven
tion also describes R-groups associated With such alpha
carbons and methods of altering these R-groups in order to
create novel terpene synthases capable of generating novel

antitumor drugs, and components of signal transduction

reaction products.

pathWays. Triterpenes can serve important functions as
membrane constituents and precursors of steroid hormones

Until the invention taught in this present application, the
active site of synthase proteins, the amino acid residues
located therein, the amino acid residues involved in
catalysis, and the con?guration of ot-carbons and R-groups

and bile acids. Polyprenols function as photoreceptive
agents and cofactor side chains, and can also exist as natural

30

polymers.

Within the active site have not been knoWn. The current

The diverse molecular compounds produced by the iso
prenoid pathWay are created from diphosphate esters of
monounsaturated isoprene units. Isoprenes are added
together in multiples of 2, 3, or 4 by prenyl transferases to

invention noW teaches the structure of synthases, as Well as
35

make C10, C15, and C20 units, respectively. The C10, C15,
and C20 molecules, named geranyl diphosphate (GPP),

for creation and production of synthase mutants that can use

farnesyl diphosphate (FPP), and geranylgeranyl diphosphate
(GGPP), respectively, serve as substrates for terpene syn
thases.

provides the means of making and using the information
obtained therefrom to develop and produce neW and novel
synthases having neW and novel synthetic capabilities. The
data generated using the methods described herein are useful
a variety of isoprenoid substrates and produce a variety of

40

isoprenoid products.
In one embodiment, the invention features an isolated

Terpene synthases catalyZe the production of isoprenoid

terpene synthase having about 20% or greater sequence

compounds via one of the most complex reactions knoWn in

identity to residues 265 to 535 of SEQ ID NO: 2. Such a

chemistry or biology. In general, terpene synthases are
moderately siZed enZymes having molecular Weights of

synthase comprises nine ot-carbons having interatomic dis
45

about 40 to 100 kD. As an enZyme, terpene synthases can be
classi?ed as having loW to moderate turnover rates coupled

With exquisite reaction speci?city and preservation of chiral
ity. Turnover comprises binding of substrate to the enZyme,
establishment of substrate conformation, conversion of sub
strate to product and product release. Reactions can be

50

performed in vitro in aqueous solvents, typically require
magnesium ions as cofactors, and the resulting products,
Which are often highly hydrophobic, can be recovered by
partitioning into an organic solvent.
Terpene synthase genes are found in a variety of organ

55

tances in Angstroms betWeen the ot-carbons that are 12.3

Angstroms of the interatomic distances shoWn in Table 6.
The center point of each ot-carbon is positioned Within a
sphere having a radius of 2.3 Angstroms. The center point of
each such sphere has the structural coordinates given in
Table 5. Each ot-carbon has an associated R-group, and the
synthase has an ordered arrangement of R-groups associated
With each alpha-carbon other than the ordered arrangements
of R-groups shoWn in Table 9. The synthase can have about
25% or greater sequence identity to residues 265 to 535 of
SEQ ID 2, or about 35% or greater sequence identity to
residues 265 to 535 of SEQ ID 2. Such a synthase can
catalyse the formation of a terpenoid product from a monot
erpene substrate, a sesquiterpene substrate, or a diterpene

isms including bacteria, fungi and plants. SWapping regions
approximating exons betWeen different terpene synthases
has identi?ed functional domains responsible for terminal
60

substrate. The product can be a cyclic terpenoid hydrocarbon
or an acyclic terpenoid hydrocarbon. Either type of product
can be hydroxylated or non-hydroxylated. The R-group

(tobacco) and Hyoscyamus muticus vetispiraa'iene synthase

associated With ot-carbon 1 can be selected from one of the

(HVS) from henbane revealed that exon 4 and exon 6,
65

folloWing groups: the group consisting of Cys, Ser, and Thr,
the group consisting of Phe, Tyr and Trp, the group consist
ing of Pro, Gly, and Ala, the group consisting of Glu and
Asp, the group consisting of Met, Ile, Val and Leu, the group
consisting of Arg and Lys, and the group consisting of Gln,

enZymatic steps. For example, Work performed on 5-epi
aristolochene synthase (TEAS) from Nicotiana tabacum

respectively, Were responsible for reaction product speci?c
ity. Combining functional domains resulted in novel
enZymes capable of synthesiZing neW reaction products

(US. Pat. No. 5,824,774).

US 6,559,297 B2
3

4

Asn and His. R-groups associated With ot-carbons 2 to 9 can

identity to residues 265 to 535 of SEQ ID NO: 2. The

be any amino acid except those having the ordered arrange
ments of Table 9. Similarly, the R-group associated With
each of ot-carbons 2—9 can be selected independently from
the group consisting of Cys, Ser and Thr, the group con

synthase can catalyse the formation of a terpenoid product
from a monoterpene substrate, a sesquiterpene substrate, or
a diterpene substrate. The product can be, for example, a

cyclic terpenoid hydrocarbon.

sisting of Phe, Tyr and Trp, the group consisting of Pro, Gly,

The invention also features an isolated protein comprising

and Ala, the group consisting of Glu and Asp, the group
consisting of Met, Ile, Val and Leu, the group consisting of
Arg and Lys, and the group consisting of Gin, Asn and His.
In these embodiments, R-groups associated With the remain
ing eight ot-carbons except those having the ordered arrange

a ?rst domain having an amino terminal end and a carboxyl

terminal end. The ?rst domain comprises amino acids that
align structurally in three-dimensional space With a glycosyl
10

ments of Table 9.

230 of glucoamylase protein databank (PDB) code 3GLY of
Aspergillus awamori and amino acids 36 to 230 of endo

In some embodiments, the ordered arrangement of

glucanase CelD PDB code 1CLC. The isolated protein also

R-groups associated With ot-carbons 1 to 9 is Trp, Ile, Thr,

Thr, Tyr, Leu, Cys, Thr and Phe, respectively, Ser, Ile, Thr,
Thr, Tyr, Leu, Cys, Thr and Tyr, respectively, Trp, Ile, Thr,
Thr, Tyr, Leu, Trp, Thr and Tyr, respectively, Ser, Ile, Thr,
Thr, Tyr, Leu, Trp, Thr and Tyr, respectively, or Glu, Ile, Thr,
Thr, Tyr, Leu, Cys, Thr and Tyr, respectively.
The invention also features a terpene synthase made by
aligning the primary amino acid sequence of a preselected
terpene synthase polypeptide to the amino acid sequence of
residues 265 to 535 of SEQ ID NO: 2, mutating a nucleic
acid encoding the preselected polypeptide at one or more
codons for nine amino acid residues in a region of the

15

20

25

30

the ?rst domain is linked to the amino terminal end of the
second domain. The second domain has about 20% or
greater sequence identity to residues 265 to 535 of SEQ ID

Angstroms of the interatomic distances given in Table 6. The
center point of each ot-carbon is positioned Within a sphere
having a radius of 2.3 Angstroms, the center point of each
sphere having the structural coordinates given in Table 5.
Each ot-carbon has an associated R-group, and the synthase
has an ordered arrangement of R-groups other than the
ordered arrangements of R-groups given in Table 9. The
protein can have about 25% or greater sequence identity to
SEQ ID NO: 2, or about 35% or greater sequence identity to
SEQ ID NO: 2. The synthase can catalyse the formation of
a terpenoid product from a monoterpene substrate, a ses

35

stroms betWeen the ot-carbons that are 12.3 Angstroms of the

cyclic terpenoid hydrocarbon. The ordered arrangement of

and carboxyl terminal end. The second domain comprises
amino acids that align structurally in three-dimensional
space With avian FPP synthase. The carboxyl terminal end of

NO: 2, and comprises nine ot-carbons having interatomic

or greater sequence identity to residues 265 to 535 of SEQ

interatomic distances given in Table 4. The center point of
each ot-carbon is positioned Within a sphere having a radius
of 2.3 Angstroms. The center point of each of the spheres has
the structural coordinates given in Table 3. Each ot-carbon
has an associated R-group, and the synthase has an ordered
arrangement of R-groups other than the ordered arrange
ments of R-groups given in Table 8. The synthase can have
about 25% or greater sequence identity to residues 265 to
535 of SEQ ID NO: 2, or about 35% or greater sequence
identity to residues 265 to 535 of SEQ ID NO: 2. The
synthase can catalyse the formation of a terpenoid product
from a monoterpene substrate, a sesquiterpene substrate, or
a diterpene substrate. The product can be, for example, a

comprises a second domain having an amino terminal end

distances in Angstroms betWeen the ot-carbons that are 12.3

polypeptide primary amino acid sequence having about 20%
ID NO: 2, the nine residues in the polypeptide aligning With
residues 273, 294, 402, 403, 404, 407, 440, 519 and 520 of
SEQ ID NO: 2; and expressing the mutated nucleic acid so
that a mutated terpene synthase is made.
The invention also features an isolated terpene synthase
having about 20% or greater sequence identity to residues
265 to 535 of SEQ ID NO: 2, the synthase comprising
sixteen ot-carbons having interatomic distances in Ang

hydrolase catalytic core, the glycosyl hydrolase catalytic
core selected from the group consisting of amino acids 36 to

quiterpene substrate, or a diterpene substrate. The product
can be, for example, a cyclic terpenoid hydrocarbon.
The invention also features an isolated synthase having a
region With about 40% or greater sequence identity to
residues 343 to 606 of SEQ ID NO: 20, Wherein one or more

40

amino acid residues of the synthase that align With amino

acid residues at positions 348, 351, 372, 375, 376, 454, 479,
480, 481, 482, 485, 519, 523, 597, 600, 601, 605, 607 and
608 of SEQ ID NO: 20 are residues other than amino acids

Y,L, C, I,T,Y,S, C, G,H,S,L, G,F, G,Y,D,YandS,
45

respectively. In some embodiments, the sequence identity
can be about 20% or greater, 25% or greater, or 35% or
greater. In some embodiments, one or more of the ordered

50

R-groups in the synthase associated With ot-carbons 1 to 16

arrangements of residues as given in Table 7 are not found
in such a synthase.
The invention also features an isolated synthase having a
region With about 40% or greater sequence identity to

can be Cys, Trp, He, He, Ser, Thr, Thr, Tyr, Leu, Cys, Val,
Thr, Tyr, Asp, Phe and Thr, respectively.

residues 316 to 586 of SEQ ID NO: 22, Wherein one or more

The invention also features an isolated terpene synthase
having about 20% or greater sequence identity to residues
265 to 535 of SEQ ID NO: 2, the synthase comprising

acid residues at positions 321, 324, 345, 348, 349, 427, 452,
453, 454, 455, 458, 492, 496, 569, 572, 573, 577, 579 and

amino acid residues of the synthase that align With amino
55

580 of SEQ ID NO: 22 are residues other than amino acids

nineteen ot-carbons having interatomic distances in Ang

C,W, N, I, T,Y, S, I, S, G, M, L, D,A, M,Y, D, H and G,

stroms betWeen the ot-carbons that are 12.3 Angstroms of the

respectively. In some embodiments, the sequence identity

interatomic distances given in Table 2. The center point of
each ot-carbon is positioned Within a sphere having a radius
of 2.3 Angstroms. The center points of each sphere have the
structural coordinates given in Table 1. Each ot-carbon has
an associated R-group, and the synthase has an ordered
arrangement of the R-groups other than the ordered arrange
ments of R-groups given in Table 7. The synthase can have
about 25% or greater sequence identity to residues 265 to
535 of SEQ ID NO: 2, or about 35% or greater sequence

60

can be about 20% or greater, 25% or greater, or 35% or
greater. In some embodiments, one or more ordered arrange

ments of residues as given in Table 7 are not found in such
a synthase.

The invention also features an isolated synthase having a
region With about 40% or greater sequence identity to
65

residues 352 to 622 of SEQ ID NO: 58, Wherein one or more

amino acid residues of the synthase that align With amino

acid residues at positions 357, 360, 381, 384, 385, 463, 487,
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488, 489, 490, 493, 528, 532, 606, 609, 610, 614, 616 and

559 of SEQ ID NO: 48 are residues other than amino acids

617 of SEQ ID NO: 58 are residues other than amino acids

Y,W,A, C, T,Y, S, S, G, M, L, G, D, L, I,Y, D,LandY,

Y,M, C,V,T, F,V,S, S, G,I,L, G, F,V,Y,D,YandT,

respectively. In some embodiments, the sequence identity

respectively. In some embodiments, the sequence identity

can be about 20% or greater, 25% or greater, or 35% or
greater. In some embodiments, one or more of the ordered

can be about 20% or greater, 25% or greater, or 35% or
greater. In some embodiments, one or more of the ordered

arrangements of residues as given in Table 7 are not found
in such a synthase.
The invention also features an isolated synthase having a
region With about 40% or greater sequence identity to

arrangements of residues as given in Table 7 are not found
in such a synthase.
The invention also features an isolated synthase having a

region With about 40% or greater sequence identity to amino
acid residues 272 to 540 encoded by SEQ ID NO: 33,

10

amino acid residues of the synthase that align With amino

acid residues at positions 312, 315, 336, 339, 340, 419, 444,
445, 446, 447, 450, 484, 488, 562, 565, 566, 570, 572 and

Wherein one or more amino acid residues of the synthase that

align With amino acid residues at positions 277, 280, 301,

573 of SEQ ID NO: 50 are residues other than amino acids

304, 305, 383, 408, 409, 410, 411, 414, 448, 452, 524, 527,
528, 532, 534 and 535 encoded by SEQ ID NOS: 33 are

residues 307 to 578 of SEQ ID NO: 50, Wherein one or more

15

residues other than amino acids G, W, I, A, S, Y, T, S, G, Y,
L, C, D, M, L, Y, D, Y and T, respectively. In some

F,W,A, M, T,Y, N, T, G, M, L, S, D, I, M,Y, D,F and S,
respectively. In some embodiments, the sequence identity
can be about 20% or greater, 25% or greater, or 35% or
greater. In some embodiments, one or more of the ordered

embodiments, the sequence identity can be about 20% or

arrangements of residues as given in Table 7 are not found
greater, 25% or greater, or 35% or greater. In some
embodiments, one or more of the ordered arrangements of 20 in such a synthase.
residues as given in Table 7 are not found in such a synthase.
The invention also features an isolated synthase having a

The invention also features an isolated synthase having a
region With about 40% or greater sequence identity to

region With about 40% or greater sequence identity to
residues 264 to 533 of SEQ ID NO: 52, Wherein one or more

amino acid residues of the synthase that align With amino

residues 319 to 571 of SEQ ID NO: 42, Wherein one or more

amino acid residues of the synthase that align With amino

25

acid residues at positions 324, 327, 348, 351, 352, 430, 455,
456, 457, 458, 461, 495, 499, 571, 574, 575, 579, 581 and

528 of SEQ ID NO: 52 are residues other than amino acids

582 of SEQ ID NO: 42 are residues other than amino acids

I,W,V,I, S,Y,T,T, G, L,V,I,N,T, S,Y,D,Y,andT,
respectively. In some embodiments, the sequence identity

C,W,L,T,S,Y,S,A, G,Y,I,A,N,A,L,Y,D,YandS,
30

can be about 20% or greater, 25% or greater, or 35% or
greater. In some embodiments, one or more of the ordered

arrangements of residues as given in Table 7 are not found
in such a synthase.
The invention also features an isolated synthase having a
region With about 40% or greater sequence identity to

acid residues at positions 269, 272, 293, 296, 297, 375, 401,
402, 403, 404, 407, 441, 445, 517, 520, 521, 525, 527 and
respectively. In some embodiments, the sequence identity
can be about 20% or greater, 25% or greater, or 35% or
greater. In some embodiments, one or more of the ordered

arrangements of residues as given in Table 7 are not found
35

in such a synthase.
The invention also features an isolated synthase having a
region With about 40% or greater sequence identity to
residues 585 to 853 of SEQ ID NO: 56, Wherein one or more

residues 579 to 847 of SEQ ID NO: 44, Wherein one or more

amino acid residues of the synthase that align With amino

amino acid residues of the synthase that align With amino

acid residues at positions 590, 593, 614, 617, 618, 696, 721,
722, 723, 724, 727, 761, 765, 837, 840, 841, 845, 847 and

acid residues at positions 584, 587, 606, 609, 610, 688, 713,
714, 715, 716, 719, 753, 757, 831, 834, 835, 839, 841 and

40

848 of SEQ ID NO: 56 are residues other than amino acids

842 of SEQ ID NO: 44 are residues other than amino acids

I, S, S,T,V,Y,S,I,A,L,V, G,N,M,F,Y,D,LandT,

V,S, G, Q,V,Y,S,V,G,L, C,W, N,V,F,Y,D,Yand G,

respectively. In some embodiments, the sequence identity

respectively. In some embodiments, the sequence identity

can be about 20% or greater, 25% or greater, or 35% or
can be about 20% or greater, 25% or greater, or 35% or 45 greater. In some embodiments, one or more of the ordered
arrangements of residues as given in Table 7 are not found
greater. In some embodiments, one or more of the ordered

arrangements of residues as given in Table 7 are not found
in such a synthase.
The invention also features an isolated synthase having a
region With about 40% or greater sequence identity to

in such a synthase.
The invention also features an isolated synthase having a
region With about 40% or greater sequence identity to
50

residues 307 to 574 of SEQ ID NO: 54, Wherein one or more

residues 495 to 767 of SEQ ID NO: 46, Wherein one or more

amino acid residues of the synthase that align With amino

amino acid residues of the synthase that align With amino

acid residues at positions 312, 315, 336, 339, 340, 418, 443,
444, 445, 446, 449, 483, 487, 560, 563, 564, 566, 568 and

acid residues at positions 500, 503, 524, 527, 528, 606, 631,
632, 633, 634, 637, 674, 678, 751, 754, 755, 759, 761 and
762 of SEQ ID NO: 46 are residues other than amino acids

569 of SEQ ID NO: 54 are residues other than amino acids
55

C,W, I, I, T,Y, S, I, S,A, I, L, D,A, I,Y, D, D and G,

F, L, A, Q, T, Y, S, I, G, Q, L, S, D, T, I, F, D, F and G,

respectively. In some embodiments, the sequence identity

respectively. In some embodiments, the sequence identity

can be about 20% or greater, 25% or greater, or 35% or
greater. In some embodiments, one or more of the ordered

can be about 20% or greater, 25% or greater, or 35% or
greater. In some embodiments, one or more of the ordered

arrangements of residues as given in Table 7 are not found
in such a synthase.
The invention also features an isolated synthase having a

60

region With about 40% or greater sequence identity to

residues 309 to 577 of SEQ ID NO: 24, Wherein one or more

amino acid residues of the synthase that align With amino

residues 295 to 564 of SEQ ID NO: 48, Wherein one or more

amino acid residues of the synthase that align With amino

acid residues at positions 300, 303, 324, 327, 328, 406, 431,
432, 433, 434, 437, 471, 475, 548, 551, 552, 556, 558 and

arrangements of residues as given in Table 7 are not found
in such a synthase.
The invention also features an isolated synthase having a
region With about 40% or greater sequence identity to

65

acid residues at positions 314, 317, 338, 341, 342, 420, 446,
447, 448, 449, 452, 485, 489, 560, 563, 564, 569, 571 and
572 of SEQ ID NO: 24 are residues other than amino acids
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C,W,N,V,T,Y,I, G, G,I,L,L,D,A,I,Y,D,Fand G,

a radius of 2.3 Angstroms. The center point of each sphere
has the structural coordinates given in Table 5. The method
then comprises synthesiZing a polypeptide that is modi?ed

respectively. In some embodiments, the sequence identity
can be about 20% or greater, 25% or greater, or 35% or
greater. In some embodiments, one or more of the ordered

from the preselected polypeptide. The modi?ed polypeptide
has one or more R-groups associated With the nine

arrangements of residues as given in Table 7 are not found
in such a synthase.
The invention also features an isolated synthase having a

ot-carbons other than the R-groups associated With the

ot-carbons in the preselected polypeptide. The synthesiZing
step can comprise the formation of a nucleic acid encoding

region With about 40% or greater sequence identity to

the preselected polypeptide in Which the coding sequence

residues 315 to 584 of SEQ ID NO: 26, Wherein one or more

amino acid residues of the synthase that align With amino

10

acid residues at positions 320, 323, 344, 347, 348, 426, 451,
452, 453, 454, 457, 492, 496, 568, 571, 572, 576, 578 and

preselected polypeptide. The preselected polypeptide can be,

579 of SEQ ID NO: 26 are residues other than amino acids

for example, any one of the polypeptides given in SEQ ID

S,W, I,A,T,Y,S,V,A, S, I,L, D,A, I,Y,D, F, and G,
respectively. In some embodiments, the sequence identity

15

can be about 20% or greater, 25% or greater, or 35% or
greater. In some embodiments, one or more of the ordered

arrangements of residues as given in Table 7 are not found
in such a synthase.
The invention also features an isolated synthase having a

The invention also features a method of using a terpene

20

amino acid residues of the synthase that align With amino

preselected polypeptide. The novel polypeptide is modi?ed
25

531 of SEQ ID NO: 28 are residues other than amino acids

A,W,V,C,G,F,T,S,C,I,M,G,N,C,S,ZD,YandS,
respectively. In some embodiments, the sequence identity
can be about 20% or greater, 25% or greater, or 35% or
30
greater. In some embodiments, one or more of the ordered

arrangements of residues as given in Table 7 are not found
in such a synthase.
The invention also features an isolated synthase having a
residues 342 to 612 of SEQ ID NO: 30, Wherein one or more

35

positions other than the amino acid residues present in the
preselected polypeptide. In some embodiments, the identi
fying step can comprise identifying siXteen amino acid
residues in the preselected polypeptide that align With amino

acid residues 270, 273, 294, 297, 298, 402, 403, 404, 407,
440, 516, 519, 520, 525, 527 and 528 of SEQ ID NO: 2, and
the synthesiZing step can comprise synthesiZing a polypep
tide that is modi?ed from the preselected polypeptide, the
modi?ed polypeptide having amino acid residues at one or
more of the siXteen positions other than the amino acid

embodiments, the identifying step can comprise identifying

acid residues at positions 347, 350, 371, 374, 375, 453, 478,
479, 480, 481, 483, 518, 522, 596, 599, 600, 604, 606 and
607 of SEQ ID NO: 30 are residues other than amino acids

by having amino acid residues at one or more of the nine

residues present in the preselected polypeptide. In some

amino acid residues of the synthase that align With amino

F, L, C,V,T,Y,S,S,A,Y,V,L, G, L,L,Y,D,F andS,

tide having a region With 20% or greater sequence identity
to residues 265 to 535 of SEQ ID NO: 2, amino acid residues
at nine positions that align With amino acid residues 273,

294, 402, 403, 404, 407, 440, 519 and 520 of SEQ ID NO:
2; and synthesiZing a polypeptide that is modi?ed from the

residues 265 to 536 of SEQ ID NO: 28, Wherein one or more

region With about 40% or greater sequence identity to

NOS: 2, 4, 6, 8, 10, 12, 20, 22, 24, 26, 28, 30, 32, 34—40, 42,
44, 46, 48, 50, 52, 54, 56, or 58.
synthase, comprising identifying, in a preselected polypep

region With about 40% or greater sequence identity to

acid residues at positions 270, 273, 294, 297, 298, 376, 401,
402, 403, 404, 407, 440, 444, 518, 521, 522, 528, 530 and

for one or more amino acids corresponding to the nine

ot-carbons is replaced by a coding sequence that codes for an
amino acid different from the amino acid present in the

nineteen amino acid residues in the preselected polypeptide
that align With amino acid residues 270, 273, 294, 297, 298,
40

376, 401, 402, 403, 404, 407, 440, 444, 516, 519, 520, 525,

respectively. In some embodiments, the sequence identity

527 and 528 of SEQ ID NO: 2, and the synthesiZing step can
comprise synthesiZing a polypeptide that is modi?ed from

can be about 20% or greater, 25% or greater, or 35% or
greater. In some embodiments, one or more of the ordered

ing amino acid residues at one or more of the nineteen

arrangements of residues as given in Table 7 are not found
in such a synthase.
The invention also features an isolated synthase having a
region With about 40% or greater sequence identity to

the preselected polypeptide, the modi?ed polypeptide hav
45

the formation of a nucleic acid encoding the preselected
polypeptide in Which the coding sequence in the nucleic acid

residues 273 to 541 of SEQ ID NO: 32, Wherein one or more

amino acid residues of the synthase that align With amino

positions other than the amino acid residues present in the

preselected polypeptide. The synthesiZing step can comprise
coding for one or more of the identi?ed amino acid residues
50

is replaced by a coding sequence that encodes an amino acid
different from the amino acid present in the preselected

acid residues at positions 278, 281, 302, 305, 306, 384, 409,
410, 411, 412, 415, 448, 452, 524, 527, 528, 533, 535 and

polypeptide. The preselected polypeptide can be, for

536 of SEQ ID NO: 32 are residues other than amino acids

eXample, any one of the polypeptides given in SEQ ID NOS:

C,W, I, I,S,Y,T, S,T,Y,L, C, D,I,T,Y,D,YandT,
respectively. In some embodiments, the sequence identity

2, 4, 6, 8, 10, 12, 20, 22, 24, 26, 28, 30, 32, 34—40, 42, 44,
55

can be about 20% or greater, 25% or greater, or 35% or
greater. In some embodiments, one or more ordered arrange

ments of residues as given in Table 7 are not found in such
a synthase.
The invention also features a method for making a terpene

46, 48, 50, 52, 54, 56, or 58. The method can further
comprise: contacting the modi?ed polypeptide With an iso
prenoid substrate under conditions effective for the com

pound to bind the polypeptide; and measuring the ability of
the modi?ed polypeptide to catalyZe the formation of a
60

reaction product from the isoprenoid substrate. The iso

synthase, comprising identifying, in a preselected polypep

prenoid substrate can be a monoterpene, a sesquiterpene, or

tide having a region With 20% or greater sequence identity
to residues 265 to 535 of SEQ ID NO: 2, nine amino acid
residues Whose ot-carbons have interatomic distances in
Angstroms betWeen the ot-carbons that are 12.3 Angstroms
of the interatomic distances given in Table 6. The center
point of each ot-carbon is positioned Within a sphere having

a diterpene.
The invention also features a method of making a terpene
65

synthase, comprising creating a population of nucleic acid
molecules that encode polypeptides, the population having
members that differ from one another at one or more of nine

codons specifying amino acids of a preselected terpene
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synthase having a region With about 20% or greater
sequence identity to residues 265 to 535 of SEQ ID NO: 2,
ot-carbons of the nine amino acids having interatomic dis

altered substrate speci?city, methods of making the same,
and procedures for generating three-dimensional structures
thereof.
Although methods and materials similar or equivalent to
those described herein can be used to practice the invention,
suitable methods and materials are described beloW. All

tances in Angstroms betWeen the ot-carbons that are 12.3

Angstroms of the interatomic distances given in Table 6. The
center point of each ot-carbon is positioned Within a sphere
having a radius of 2.3 Angstroms, and the center point of
each sphere has the structural coordinates given in Table 5.
In some embodiments, the codons specify amino acids as
described in Tables 1—2 or 3—4 of a preselected terpene

publications, patent applications, patents and other refer
ences mentioned herein are incorporated by reference in
10

synthase. A portion, or all, of the nucleic acid population is
expressed so that a population of polypeptides is made. At

the present invention Will become apparent from the speci
?cation.

least one member of the population of polypeptides is a

mutant terpene synthase. The expressing step can comprise
in vitro transcription and in vitro translation of the nucleic
acid population. In some embodiments, the expressing step

their entirety.
Other aspects, embodiments, advantages, and features of

BRIEF DESCRIPTION OF DRAWINGS
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FIG. 1. Schematic representation of tobacco 5-epi

comprises cloning members of the nucleic acid population
into an expression vector, introducing the expression vector

aristolochene synthase (TEAS) With bound farnesyl
hydroxyphosphonate (FTP), prepared using the RIBBONS

into host cells and expressing the cloned nucleic acid
population members in the host cells so that the population

softWare program of Carson, M. and Bugg, C., J. Mol.

Graphics 4:121 (1986). Cylinders 1—8 and A represent
ot-helices in the NH2-terminal domain; cylinders C, D, D1,
D2, E, F, G1, G2, H1, H2, H3, I and ot-l represent ot-helices

of polypeptides is made. The preselected terpene synthase
polypeptide can be a monoterpene synthase, a sesquiterpene
synthase, or a diterpene synthase. The host cells can be

prokaryotic cells or eukaryotic cells, including, Without
limitation, bacterial cells, fungal cells, and animal cells, e.g.,

in the COOH-terniinal domain.
FIG. 2. Structure of tWenty natural amino acids shoWing
25

mammalian cells or insect cells. The host cells can also be
plant cells, e.g., a cell from a Graminaceae plant, a cell from
a Legumineae plant, a cell from a Solanaceae plant, a cell
from a Brassicaeae plant or a cell from a Conifereae plant.
The invention also features a nucleic acid encoding a

synthase as described herein, and a host cell containing such
a nucleic acid. The invention also features a transgenic plant
containing such a nucleic acid, or a transgenic animal cell
culture containing such a nucleic acid.
In some embodiments, a synthase polypeptide of the

matogram of terpenoid hydrocarbon products made by
TEAS and mutant TEAS enZymes using GGPP as a sub
strate. DM: W273S/C440W mutant TEAS enZyme.

FIG. 4. Autoradiogram of an argentation thin-layer chro

matogram of terpenoid hydrocarbon products made by
TEAS and mutant TEAS enZymes using FPP as a substrate.

BRIEF DESCRIPTION OF TABLES
35

invention comprises a domain that contains an active site

Table 1. X-ray crystallographic structural coordinates for
19 ot-carbons found in the active site of a terpene synthase.
Table 2. Interatomic distances in Angstroms betWeen each
ot-carbon of Table 1. Each ot-carbon occupies a sphere
having a radius of 2.3 Angstroms. Interatomic distances are

comprised of nine ot-carbon atoms having the coordinates of
Table 5, and interatomic distances betWeen the ot-carbons
12.3 angstroms of the distances given in Table 5. The
ot-carbon atoms align structurally in three dimensional space
in the presence or absence of bound substrate or substrate

analogue, With avian FPP synthase. In another embodiment,
a synthase of this invention comprises the folloWing:
a
?rst domain containing amino acid residues that align in
three-dimensional space (in solution or crystal form, and

ot-carbons and associated R-groups.
FIG. 3. Autoradiogram of an argentation thin-layer chro

45

calculated from the center point of each sphere.
Table 3. X-ray crystallographic structural coordinates for
16 ot-carbons found in the active site of a terpene synthase.
Table 4. Interatomic distances in Angstroms betWeen each
ot-carbon of Table 3. Each ot-carbon occupies a sphere

either having a bound or unbound substrate) With a glycosyl

having a radius of 2.3 Angstroms. Interatomic distances are

hydrolase catalytic core selected from the group consisting

calculated from the center point of each sphere.
Table 5. X-ray crystallographic structural coordinates for
nine ot-carbons found in the active site of a terpene synthase.
Table 6. Interatomic distances in Angstroms betWeen each
ot-carbon of Table 5. Each ot-carbon occupies a sphere

of (a) amino acids 36—230 of glycosyl hydrolase (PDB code
3GLY) of Aspergillus awarmori, and (b) amino acids
36—230 of endogluconase CellB (PDB code 1CLC), and (ii)
a second domain that aligns structurally in three dimensional
space With or Without substrate or substrate analogues bound

having a radius of 2.3 Angstroms. Interatomic distances are

in the active site With avian FPP synthase. The second
domain contains an active site comprised of nine, sixteen or
nineteen ot-carbon atoms having the structural coordinates
and interatomic distances of Tables 1—2, 3—4 or 5—6. These

calculated from the center point of each sphere.
Table 7. Ordered arrangement of Regroups not found
55

ot-carbon atoms have R-groups attached thereto that can

interact, either directly or indirectly, With an isoprenoid
substrate.
The invention also features a method for generating

mutant terpene synthases possessing catalytic activity. The
method comprises the steps of (a) providing a crystallo
graphic model of a preselected catalytically active terpene
synthase having an active site, and (b) using the model to
design a terpene synthase having at least one altered
R-group in the active site relative to the preselected syn

thase. The invention also features terpene synthases having

65

associated With the ot-carbons of Table 1.
Table 8. Ordered arrangement of R-groups not found
associated With the ot-carbons of Table 3.
Table 9. Ordered arrangement of R-groups not found
associated With the ot-carbons of Table 5.

Table 10. X-ray structural coordinates for TEAS having
the substrate analog FHP bound in the active site.
Table 11. X-ray structural coordinates for TEAS in the
absence of substrate.
Table 12. Alignment of residues 265—535 of TEAS With
a limonene synthase, SEQ ID NO: 22, using the BLASTp

alignment program.
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Table 13. Alignment of residues 579 to 847 of SEQ ID

SEQ ID NO:25 is the DNA coding sequence for a sage

NO:44 With SEQ ID NO:26, using the BLASTp program.

bornyl diphosphate synthase. Genbank Accession No:

Table 14. Alignment of residues 265 to 535 of TEAS With

AF051900.
SEQ ID NO:26 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:25.
SEQ ID NO:27 is the DNA coding sequence for a mint
E-b-farnesene synthase. Genbank Accession No: AF 024615.
SEQ ID NO:28 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:27.
SEQ ID NO:29 is the DNA coding sequence for a grand
?r myrcene synthase. Genbank Accession No: U87908.
SEQ ID NO:30 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:29.
SEQ ID NO:31 is the DNA coding sequence for a potato

SEQ ID NO:48, using the BLASTp program.
Table 15. Alignment of residues 307 to 593 of SEQ ID
NO:50 With SEQ ID NO:56 using the BLASTp program.
BRIEF DESCRIPTION OF THE SEQUENCE
LISTING

SEQ ID NO:1 is the DNA coding sequence for a tobacco

5-epi-aristolochene synthase (TEAS) protein. Genbank No:
Q40577.
SEQ ID NO:2 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:1.
SEQ ID NO:3 is the DNA coding sequence for a TEAS
protein in Which the codon for Trp273 has been changed to

15

vetaspiradiene synthase. Genbank Accession No:
AB022598.
SEQ ID NO:32 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:31.

a codon for Glu.

SEQ ID NO:4 is the amino acid sequence for the W273E

protein encoded by the TEAS DNA of SEQ ID NO:3.

SEQ ID NO:33 is the genomic DNA coding sequence for

SEQ ID NO:5 is the DNA coding sequence for a TEAS

protein in Which the codon for Tyr520 has been changed to
a codon for Phe.

SEQ ID NO:6 is the amino acid sequence for the Y520F

25

protein encoded by the TEAS DNA of SEQ ID NO:5.

a cotton delta-cadinene synthase. Genbank Accession No:
Y18484.
SEQ ID NOS:34—40 are the amino acid sequences for the
eXons encoded by the DNA of SEQ ID NO:33.
SEQ ID NO:41 is the DNA coding sequence for a castor

bean casbene synthase. Genbank Accession No: L32134.
SEQ ID NO:42 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:41.
SEQ ID NO:43 is the DNA coding sequence for a yeW
taXadiene synthase. Genbank Accession No: U48796.
SEQ ID NO:44 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:43.
SEQ ID NO:45 is the DNA coding sequence for a grand

SEQ ID NO:7 is the DNA coding sequence for a TEAS

protein in Which the codon for Tyr527 has been changed to
a codon for Phe.

SEQ ID NO:8 is the amino acid sequence for the Y527F

protein encoded by the TEAS DNA of SEQ ID NO:7.
SEQ ID NO:9 is the DNA coding sequence for a TEAS

protein in Which the codon for Trp273 has been changed to
a codon for Ser and the codon for Cys440 has been changed

35
to a codon for Trp.
?r E-alpha-bisabolene synthase. Genbank Accession No:
SEQ ID NO:10 is the amino acid sequence for the
AF006194.

W273S/C440W protein encoded by the TEAS DNA of SEQ
ID N019.

SEQ ID NO:11 is the DNA coding sequence for TEAS
proteins in Which the codons for Tyr406 and Leu407 have
each been changed to the nucleotides NNS.
SEQ ID NO:12 is the amino acid sequence for the

population of Y406X/L407X proteins encoded by the TEAS
DNA of SEQ ID NO:11, Where X is any naturally occurring

45

amino acid.
SEQ ID NO:13 is a DNA primer sequence.
SEQ ID NO:14 is a DNA primer sequence.
SEQ ID NO:15 is a DNA primer sequence.
SEQ ID NO:16 is a DNA primer sequence.
SEQ ID NO:17 is a DNA primer sequence.
SEQ ID NO:18 is a DNA primer sequence.
SEQ ID NO:19 is the DNA coding sequence for a grand

?r pinene synthase. Genbank Accession No: U87909.
SEQ ID NO:20 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:19.

?r gamma-humulene synthase. Genbank Accession No:
U92267.

SEQ ID NO:50 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:49.
SEQ ID NO:51 is the DNA coding sequence for a tomato
germacrene C synthase. Genbank Accession No: AF 035 631.
SEQ ID NO:52 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:51.
SEQ ID NO:53 is the DNA coding sequence for a
55

SEQ ID NO:21 is the DNA coding sequence for a

spearmint limonene synthase. Genbank Accession No:
L13459.
SEQ ID NO:22 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:21.
SEQ ID NO:23 is the DNA coding sequence for a sage 1,
8 cineole synthase. Genbank Accession No: AF051899.
SEQ ID NO:24 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:23.

SEQ ID NO:46 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:45.
SEQ ID NO:47 is the DNA coding sequence for a grand
?r delta-selinene synthase. Genbank Accession No: U92266.
SEQ ID NO:48 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:47.
SEQ ID NO:49 is the DNA coding sequence for a grand
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sage+sabinene synthase. Genbank Accession No:
AF051901.
SEQ ID NO:54 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:53.
SEQ ID NO:55 is the DNA coding sequence for a grand
?r abietadiene synthase. Genbank Accession No: U50768.
SEQ ID NO:56 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:55.
SEQ ID NO:57 is the DNA coding sequence for a grand
?r limonene synthase. Genbank Accession No. AF006193.
SEQ ID NO:58 is the amino acid sequence for the protein
encoded by the DNA of SEQ ID NO:57.
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DETAILED DESCRIPTION

non-mutant synthase in the ordered arrangement of
R-groups associated With the nine ot-carbons. A mutant
synthase has an ordered arrangement of R-groups on the
nine ot-carbons other than the ordered arrangements of
R-groups listed in Table 9. R-groups associated With other
ot-carbons of the synthase primary amino acid sequence may

The following terms are used herein:
“(x-carbon” refers to the chiral carbon atom found in an

amino acid residue. Four substituents are covalently bound
to the ot-carbon, including an amino group, a carboxyl
group, a hydrogen atom, and an R-group.
“R-group” refers to a substituent attached to the ot-carbon
of an amino acid residue that is not involved in peptide bond
formation in a protein. An R-group is an important deter
minant of the overall chemical character of an amino acid.

or may not be the same as in a non-mutated synthase.
In some embodiments, a mutant synthase refers to a
10

The tWenty naturally occurring amino acids found in pro
teins and the R-groups associated With the ot-carbon of each
amino acid are listed in FIG. 2. The three-letter and one

letter abbreviations for naturally occurring amino acids are
sometimes used herein to refer to the R-group associated
With a particular amino acid.

15

“Naturally occurring amino acid” includes L-isomers of
the tWenty amino acids naturally occurring in proteins.
Naturally occurring amino acids are glycine, alanine, valine,

or may not be the same as in a non-mutated synthase.
In some embodiments, a mutant synthase refers to a

glutamine, arginine, and lysine. Unless specially indicated,
25

L-form. Three-letter and one-letter abbreviations are some

times used herein to refer to naturally occurring amino acids.
These abbreviations are knoWn in the art.
“Unnatural amino acid” includes amino acids that are not

nates of Table 1 or coordinates Which can be rotated and/or

acids included herein are racemic mixtures of selenocysteine
and selenomethionine. In addition, unnatural amino acids
include the D or L forms of norleucine, para

nitrophenylalanine, homophenylalanine, para
35

ordered arrangements of R-groups listed in Table 7.
R-groups associated With other ot-carbons of the synthase

occurring or unnatural amino acid having an R-group that
carries a positive charge under normal physiological condi

primary amino acid sequence may or may not be the same
as in a non-mutated synthase.

tions. Examples of positively charged, naturally occurring
amino acids include arginine and lysine.
“Negatively charged amino acid” includes any naturally

ditions. Examples of negatively charged, naturally occurring

45

amino acids include aspartic acid and glutamic acid.
“Hydrophobic amino acid” includes any naturally occur
ring or unnatural amino acid having an uncharged, nonpolar
side chain under normal physiological conditions. Examples
of naturally occurring hydrophobic amino acids are leucine,
isoleucine, valine and methionine.
“Hydrophilic amino acid” includes any naturally occur
ring or unnatural amino acid having a charged polar side

chain. Examples of naturally occurring hydrophilic amino

“Nonmutated synthase” or “non-mutant synthase”
includes a synthase having a primary amino acid sequence
comprising nine, sixteen, or nineteen amino acid residues.
The center point of each ot-carbon of these residues is
positioned Within a sphere having a radius of 2.3 Angstroms;
the center points of the spheres have the three dimensional
coordinates of Tables 5, 3, or 1, respectively, or coordinates
Which can be rotated and/or translated to coincide With the
coordinates of Tables 5, 3, or 1. The relative interatomic

55

distances betWeen the nine, sixteen, or nineteen ot-carbons is
12.3 angstroms of the interatomic distances given in Tables
6, 4, or 2, respectively. Each ot-carbon has an associated
R-group. Anon-mutant synthase has an ordered arrangement
of R-groups on the nine, sixteen, or nineteen ot-carbons as

listed in Tables 9, 8, or 7, respectively.

acids include serine, threonine and cysteine.
“Mutant terpene synthase” or “mutated terpene synthase”
refers to a synthase polypeptide having a primary amino acid

“Degenerate variations thereof” refers to variants of a

gene coding sequence by Which the same polypeptide is
encoded by different nucleotide sequences, due to the degen
eracy of the genetic code. For example, synthases of the
present invention have a primary amino acid sequence.
Degenerate synthase variations are different nucleic acid
coding sequences that nevertheless encode the same primary
amino acid sequence due to the degeneracy of the genetic

sequence. The center point of the ot-carbon of nine residues
of the polypeptide is positioned Within a sphere having a
radius of 2.3 Angstroms; the center points of the nine
spheres have the structural coordinates of Table 5 or coor
dinates Which can be rotated and/or translated to coincide
With the coordinates of Table 5. The relative interatomic

distances betWeen the nine ot-carbons is 12.3 angstroms of
the interatomic distances given in Table 6. Each ot-carbon
has an associated R-group. Amutant synthase differs from a

ordered arrangement of R-groups associated With the nine
teen ot-carbons. A mutant synthase has an ordered arrange
ment of R-groups on the nineteen ot-carbons other than the

homoarginine, D-phenylalanine, and the like.
“Positively charged amino acid” includes any naturally

occurring or unnatural amino acid having an R-group that
carries a negative charge under normal physiological con

synthase in Which the center point of the ot-carbon of
nineteen residues of the polypeptide is positioned Within a
sphere having a radius of 2.3 Angstroms; the center points
of the nineteen spheres have the three dimensional coordi
translated to coincide With the coordinates of Table 1. The
relative interatomic distances betWeen the nineteen
ot-carbons is 12.3 angstroms of the interatomic distances
given in Table 2. Each ot-carbon has an associated R-group.
A mutant synthase differs from a non-mutant synthase in the

naturally found in proteins. Examples of unnatural amino

?uorophenylalanine, 3-amino-2-benZylpropionic acid,

coordinates Which can be rotated and/or translated to coin
cide With the coordinates of Table 3. The relative interatomic
distances betWeen the nine ot-carbons is 12.3 angstroms of
the interatomic distances given in Table 4. Each ot-carbon
has an associated R-group. Amutant synthase differs from a
non-mutant synthase in the ordered arrangement of
R-groups associated With the sixteen ot-carbons. A mutant
synthase has an ordered arrangement of R-groups on the
sixteen ot-carbons other than the ordered arrangements of

R-groups listed in Table 8. R-groups associated With other
ot-carbons of the synthase primary amino acid sequence may

leucine, isoleucine, serine, methionine, threonine,

phenylalanine, tyrosine, tryptophan, cysteine, proline,
histidine, aspartic acid, asparagine, glutamic acid,
all amino acids referred to in this application are in the

synthase in Which the center point of the ot-carbon of sixteen
residues of the polypeptide is positioned Within a sphere
having a radius of 2.3 Angstroms; the center points of the
sixteen spheres have the structural coordinates of Table 3 or

65

code.
“Expression” refers to transcription of a gene or nucleic
acid molecule and the translation of that nucleic acid into a
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polypeptide. Expression of genes also involves processing

Blundel, T. L., and Johnson, N. L., Protein Crystallography,
Academic Press (1976).

of RNA into mRNA in eukaryotic systems. It is not neces
sary for the genes to integrate into the genome of a cell in
order to achieve expression. This de?nition is not limited to
expression in a particular system or a particular cell type and

“Unit cell” refers to a basic parallelepiped shaped block.
Regular assembly of such blocks may construct the entire
volume of a crystal. Each unit cell comprises a complete
representation of the unit pattern, the repetition of Which
builds up the crystal.

includes, Without limitation, stable, transient, in vitro, and in
vivo expression.
“Promoter” and “promoter regulatory element”, refers to

“Mutagenesis” refers to the substitution of a different

a nucleic acid that is involved in controlling expression of a
gene. Promoter regulatory elements, and the like, from a
variety of sources can be used ef?ciently to promote gene

amino acid residue at a particular position in the primary
amino acid sequence of a protein, thereby changing the
R-group present at that position. Mutagenesis can be most

10

expression. Promoter regulatory elements include

easily performed by changing the coding sequence of a

constitutive, tissue-speci?c, developmental-speci?c,

nucleic acid encoding the protein so that the coding

inducible, subgenomic promoters, and the like. Promoter
regulatory elements may also include certain enhancer ele
ments or silencing elements that improve or regulate tran

sequence in the nucleic acid speci?es an amino acid residue
15

scriptional ef?ciency.
“Active Site” refers to a site in a terpene synthase that

binds the hydrophobic portion of a terpene substrate, GPP,
FPP, and/or GGPP. The active site can, under certain
conditions, catalyZe a biosynthetic reaction that alloWs one
or more reaction products to be produced.
“Altered enZymatic speci?city” includes an alteration in
the ability of a mutant synthase to use a particular terpene
substrate or a change in the pro?le of reaction product(s)
from a mutant synthase, compared to the substrate speci?c

25

elements Within a crystal.
“Molecular replacement” refers to the generation of a
preliminary model of a synthase Whose structural coordi
nates are unknoWn, by orienting and positioning a molecule
Whose structural coordinates are knoWn Within the unit cell
of the unknoWn crystal so as best to account for the observed
diffraction pattern of the unknoWn crystal. Phases can then
be calculated from this model and combined With the

observed amplitudes to give an approximate Fourier syn
thesis of the structure Whose coordinates are unknoWn. This
in turn can be subject to any of the several forms of
re?nement to provide a ?nal, accurate structure of the

ity of and the reaction products made by a corresponding
non-mutated synthase. Altered speci?city may include the
ability of a synthase to exhibit different enZymatic param
eters relative to a non-mutated synthase (Km, Vmax, etc),

unknoWn crystal (Lattman, E., 1985, in Methods in
EnZymology, 115:55—77; Rossmann, M G., ed., “The

and/or to produce products that are different from those that
are produced by a corresponding non-mutant synthase.

Molecular Replacement Method” 1972, Int. Sci. Rev. Ser.,
No. 13, Gordon & Breach, NeW York). Using structure
coordinates and interatomic distance matrices, molecular

“Structure coordinates” or “structural coordinates” refers

to Cartesian coordinates (x, y, and Z positions) derived from

different from the residue initially present at that position.
“Space Group” refers to the arrangement of symmetry

mathematical equations involving Fourier synthesis as

replacement may be used to determine the structural coor
dinates of a crystalline mutant, homologue, or a different

determined from patterns obtained via diffraction of a mono

crystal form of terpene synthase.

chromatic beam of X-rays by the atoms (scattering centers)

“Recombinant protein” includes a protein that is chemi
cally synthesiZed or derived biosynthetically from an iso
lated gene.
“Gene” includes naturally derived or genetically manipu
lated nucleic acids that contain the information needed to

35

of a synthase molecule in crystal form. Diffraction data are

used to calculate electron density maps of repeating protein
units in the crystal (unit cell). Electron density maps are used
to establish the positions of individual atoms Within a
crystal’s unit cell. The absolute values for structural coor

dinates listed herein convey relative spatial relationships
betWeen atoms because the absolute values ascribed to 45

structural coordinates can be changed by rotational and/or
translational movement along the x, y and/or Z axes, together
or separately, While maintaining the same relative spatial
relationships among atoms. Thus, a terpene synthase Whose

produce a polypeptide.
“Nucleic acid” includes any genetic material comprised of

the nucleotides guanine, adenine, thymine, cytosine, uracil,
inosine and the like. Nucleic acids may be single-, double-,
or triple stranded. Nucleic acids may be deoxyribonucleic
acid or ribonucleic acid.

absolute values for a set of structural coordinates can be

“Genetically manipulated” includes genes that have been

rotationally or translationally adjusted to coincide With the
particular values listed in Tables 1, 3, or 5 is considered to

modi?ed to contain a different nucleotide sequence from that

present in a preselected nulceic acid. Genes can be manipu

lated by synthetically or via traditional cloning, PCR, chemi
have the same structural coordinates as those of Tables 1, 3
cal gene synthesis, direct or random mutagenesis, and gene
or 5. An example of structural coordinates that coincide With
the absolute values listed herein after rotation and/or trans 55 shuffling. Genetically manipulated also includes the process
of making genes that are degenerate variations of nucleic
lation are the coordinates of Table 11.
acids encoding preselected proteins.
“Heavy atom derivatiZation” refers to a method of pro
“First domain” includes polypeptides having a ?rst and

ducing a chemically modi?ed form of a synthase crystal. In
practice, a crystal is soaked in a solution containing heavy

second end Wherein the ?rst end can have an amino terminal
amino acid With a free amino group and can be linked by a
peptide bond to a second amino acid. The ?rst end may also

atom salts or organometallic compounds, e. g., lead chloride,

gold thiomalate, thimerosal, uranyl acetate and the like,

be modi?ed through acetylation and the like. The second end

Which can diffuse through the crystal and bind to the
protein’s surface. Locations of the bound heavy atoms can

of the ?rst domain may or may not have a free carboxyl
terminal group.

be determined by X-ray diffraction analysis of the soaked
crystal. The information is then used to construct phase
information Which can then be used to construct three
dimensional structures of the enZyme as described in
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“Second domain” includes polypeptides having a ?rst and
second end Wherein the ?rst end can have an amino terminal
amino acid and can be linked by a peptide bond to a second
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amino acid. The second end of the second domain may or
may not have a carboXyl terminal group. Typically, the ?rst
end of the second domain is linked to the second end of the
?rst domain via a peptide bond.

substrate analog. Coordinates for a synthase With a substrate
analog bound in the active site are given in Table 10.
Coordinates for a synthase in the absence of a substrate
analog bound in the active site are given in Table 11. Those
skilled in the art understand that a set of structure coordi

“Isoprenoid substrate” refers to the C10, C15, and C20

nates determined by X-ray crystallography is not Without

molecules, named geranyl diphosphate (GPP), farnesyl
diphosphate (FPP), and geranylgeranyl diphosphate

standard error. Therefore, for the purpose of this invention,
any set of structure coordinates Wherein the active site
ot-carbons of a synthase, synthase homologue, or mutants

(GGPP), respectively.
“Sequence identity” or “percent sequence identity” refers
to the percentage of amino acids or nucleotides that occupy
the same relative position When tWo protein sequences or
nucleic acid sequences, a query sequence and a subject
sequence, are aligned. The number of amino acid or nucle
otide residues that are identical betWeen both the subject and

10

query sequences are counted, divided by the number of
residues in the query sequence, and multiplied by 100. The

15

process is repeated until the alignment resulting in the
highest percent sequence identity is found. Percent sequence
identity can be determined by visual inspection and/or by
using various computer programs, e.g., MegAlign
(DNASTAR, Inc., Madison, Wis.) or BLAST programs

A schematic representation of the three-dimensional
shape of a synthase is shoWn in FIG. 1 Which Was prepared

20

25

active site can be determined in three-dimensional space.
The invention also relates to structural coordinates of the
synthases, use of the structural coordinates to develop struc

30

develop synthases in Which R-groups associated With active

coordinates of Table 3 and the relative distances 12.3
angstroms of the distances given in Table 4. The active site
ot-carbons of Table 3 generally are not all contiguous, i.e.,
are not adjacent to one another in the primary amino acid
sequence of a synthase, due to intervening amino acid
residues betWeen various active site ot-carbons. On the other
hand, it should be appreciated that some of the active site

In the embodiment depicted in the TEAS Y527F protein
(SEQ ID N018), for example, active site ot-carbons are
adjacent to one another in the primary amino acid sequence
at positions 402, 403 and 404, respectively, Whereas active
site ot-carbons at residues 273 and 294 are separated and

thus are not adjacent. Thus, the numbering of active site
35

40

tural information related to synthase homologues, mutants,
and the like, and to crystal forms of such synthases.
Furthermore, the invention provides a method Whereby
ot-carbon structural coordinates for atoms comprising the
active site of a preselected terpene synthase can be used to

comprises siXteen active site ot-carbons having the structural

ot-carbons can be adjacent to one another in some instances.

strate GGPP.

The present invention relates to terpene synthases and
mutants thereof from Which the position of speci?c ot-carbon
atoms and R-groups associated thereWith comprising the

by RIBBONS (Carson and Bugg, 1986, J. Mol. Graphics,
4:121). The synthase shoWn in FIG. 1 consists entirely of
ot-helices and short connecting loops and turns, organiZed
into ?rst and second structural domains.
In one embodiment, an isolated synthase of the invention

sequence, i.e., ot-helices, [3-sheets and loops.
“Monoterpene product” refers to linear, cycliZed, and/or
hydroXylated reaction products made from the substrate
GPP. “Sesquiterpene product” refers to linear, cycliZed,
and/or hydroXylated reaction products made from the sub
strate FPP. “Diterpene product” refers to linear, cycliZed,
and/or hydroXylated reaction products made from the sub

angstroms When superimposed using the structural coordi
nates listed in Table 1, 3, or 5, are considered identical.

available on the World Wide Web from the National Center
for Biotechnology Information (NCBI). Gaps of one or more
residues may sometimes be inserted to maXimiZe sequence

alignments to structurally conserved domains of the query

thereof, have a root mean square deviation less than 12.3

ot-carbons given in Tables 1, 2, 3, 4, 5, or 6 is merely for
convenience and such ot-carbons may reside at any position
in the primary amino acid sequence that achieves the struc
tural coordinates given in Tables 1, 3, or 5 and the relative
interatomic distances 12.3 angstroms given in Tables 2, 4, or
6.
An appropriate combination of R-groups, linked to active
site ot-carbons, can facilitate the formation of one or more

desired reaction products. The combination of R-groups
selected for use in a terpene synthase of the invention can be
45

any combination other than the ordered arrangements of

R-groups and corresponding active site ot-carbons shoWn in

site ot-carbon atoms are different from the R-groups found in

Tables 7, 8, or 9. An illustrative eXample of a suitable

the preselected terpene synthase. In addition, the present
invention provides for the production of novel terpene

Ser, Thr, Thr, Tyr, Leu, Cys, Val, Thr, Phe, Asp, Tyr and Thr,

synthases based on the structural information provided

arrangement of R-groups and ot-carbons is Cys, Trp, Ile, Ile,
50

herein and for the use of such synthases to make a variety of

isoprenoid compounds.
The present invention further provides, for the ?rst time,
crystals of a synthase, as exempli?ed by tobacco 5epi
aristolochene synthase (TEAS), Which are groWn in the

R-groups and ot-carbons is Cys, Trp, Ile, Ile, Ser, Thr, Thr,
Tyr, Leu, Cys, Val, Thr, Tyr, Asp, Phe, and Thr at active site
55

presence or absence of substrate and substrate analogues,
thus alloWing de?nition of the structural coordinates asso
ciated thereWith. The structural coordinates alloW determi
nation of the ot-carbon atoms comprising the active site and

R-groups associated thereWith. The crystals of the present
invention belong to the tetragonal space group P41212; the

amino acid sequences as listed in SEQ ID NO:4, SEQ ID

60

and degenerate variations thereof. Typically, R-groups found
on active site ot-carbons are those found in naturally occur

ring amino acids. See, e.g., FIG. 2. In some embodiments,

hoWever, R-groups other than naturally occurring amino

a=b, ot=90°, [3=90°, and y=90°.
lution of about 2.2 to about 2.8 angstroms for a synthase in
the presence and in the absence of bound substrate or

alpha-carbons 1 to 16, respectively, of Table 3. In some
embodiments, a synthase of the invention may have primary

NO:6, SEQ ID NO:8, and SEQ ID NO:10, DNA molecules
encoding the same, Which are listed in SEQ ID NO:3, SEQ
ID NO:5, SEQ ID NO:7, and SEQ ID NO:9, respectively,

unit cell dimensions vary by a feW angstroms betWeen
crystals but on average a=126 angstroms, c=122 angstroms,
Structural coordinates are preferably obtained at a reso

associated With active site ot-carbons 1 to 16, respectively, of
Table 3. Another eXample of a suitable arrangement of

acids can be used.
65

Some arrangements of R-groups and active site ot-carbons
result in mutant terpene synthases that form reaction prod
ucts. Such enZymatically active synthases and their corre
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sponding genes are useful to make known terpenoid

ot-carbons in a preselected polypeptide that have the struc
tural coordinates and interatomic distances of Tables 1—2,
3—4 or 5—6. The preselected polypeptide is used as the

hydrocarbons, e.g., monoterpenes such as pinene, sesquit
erpenes such as delta-cadinene and diterpenes such as abi

etadiene. Other enZymatically active synthases can be used

subject sequence in the alignment, e.g., the full-length

to make novel terpenoid products.
Some arrangements of R-groups and active site ot-carbons

primary amino acid sequence, a region 190 residues in
length, a region 220 residues in length, or a region 300
residues in length. The alignment can use residues 265 to
535 of TEAS (SEQ ID NO: 2), Which includes the ot-carbons
of Tables 1, 3 or 5, as the query sequence to align With the

may result in mutant terpene synthases that do not form
reaction product(s) at a desired rate. Such synthases and
their genes are useful as controls in analyses of product

formation by enZymatically active mutant synthases. Such
synthases and their genes can also be useful in analyses of
translation of enZymatically active mutant synthase genes,

10

the query sequence can be aligned using the BLASTp 2.0.9

or as nutritional supplements. Such synthases can be

attached to Sepharose beads and used for affinity puri?cation
of isoprenoid compounds from crude preparations. In
addition, such synthases and their genes can also be useful
to develop reagents for various purposes, e.g., immunologi
cal reagents to monitor expression of a terpene synthase
protein or nucleic acid probes or primers to monitor inher
itance of a terpene synthase gene in a plant breeding
program.

15

scoring matrix, an expect value of 10, a gap open value 13,
an xidropoff value of 50, a gap extension value of 2, a
WordsiZe of 3 and no ?ltering of loW complexity sequences.
20

In some embodiments, the ot-carbon backbone of a syn

25

and the ot-carbon backbone of a synthase second domain,

35

residues) helices surrounding a surface cavity ?lled by
40

hydrophobic and aromatic-rich active site pocket. Typically,
the second domain contains a substrate binding site. As

exempli?ed in FIG. 1, helix H is disrupted betWeen seg
ments H1 and H2 by an amino acid such as proline, but its

interhelical packing With helix G is accommodated by a
corresponding kink in helix G betWeen G1 and G2. Within
this kink, hydrogen bonds betWeen a hydroxyl group, such

speci?c residues that align With the TEAS residues corre
sponding to those listed in Tables 1, 3, or 5. In some cases,
the output of the computer program alignment identi?es a

speci?c residue in the preselected polypeptide for each of

ot-barrel made up of eight short (10 to 15 amino acid
ordered Water molecules When hydrated. The second domain
comprises a tWo-layered barrel of ot-helices surrounding a

sequence identity to residues 265—535 of TEAS, e.g., 20%
or greater sequence identity, 25% or greater sequence
identity, 35% or greater sequence identity, 40% or greater
sequence identity, 50% or greater sequence identity, 60% or
greater sequence identity, 70% or greater sequence identity,
or 80% or greater sequence identity are examined for

30

is comprised of 9, 16, or 19 amino acid residues With
ot-carbon structural coordinates as listed in Tables 1, 3, or 5
and interatomic distances as described in Tables 2, 4, or 6.
Such ot-carbons have an ordered arrangement of R-groups
different from that observed in a non-mutated synthase.
In the present invention, the ?rst domain forms a tWisted

Other parameter values can also be used, e.g., a gap exten
sion value from 0 to 4. See Altschul, et al., Nucl. Acids Res.
25:3389—3402.

Regions of the preselected polypeptide With signi?cant

Which contains the active site, aligns structurally With avian

farnesyl diphosphate synthase (FPS), Wherein the active site

computer program With a BLOSUM 62 scoring matrix, an
expect value of 10, a gap open value of 11, an xidropoff
value of 50, a gap extension value of 1, a WordsiZe of 3 and
no ?ltering of loW complexity sequences. As an alternative,
the BLASTp 2.0.9 program can be used With a BLOSUM 50

thase ?rst domain aligns structurally With the catalytic core

of glycosyl hydrolases, as exempli?ed by glucoamylase
(Brookhaven Protein Database (PDB) code 3GLY) from
Aspergillus awamori (Aleshin et al., 1994, J. Mol. Biol.,
238:575) and endoglucanase CelD (PDB code ICLC) from
Clostridium thermocelum (Juy et al., 1992, Nature, 357:89),

preselected polypeptide. The preselected polypeptide and

45

the nine, sixteen, or nineteen residues in the query sequence
having the structural coordinates and interatomic distances
of Tables 1—2, 3—4 or 5—6, With or Without gaps introduced
by the alignment program. In other cases, a gap is introduced
by the alignment program in either the query sequence or the
subject sequence such that no direct alignment or a mis
alignment occurs betWeen one or more of the nine, sixteen,
or nineteen residues in the query sequence that are of

interest. In either case, the output can be visually inspected,
and speci?c residues can be chosen in the subject sequence
after adjusting the alignment so that alpha-helices and
beta-sheet regions in the query sequence are maintained and
that gaps or insertions in the subject sequence align With
loop regions of the query sentence.

as that found on a threonine, and the carbonyl oxygen of

Sequence alignments suggest that other terpene synthases

other amino acids disrupt the main chain intrahelical hydro
gen bonding of helix G thus assisting in producing the

have regions With 20% or greater sequence identity to
residues 265—535 of TEAS. Therefore, a region of a terpene
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structure as determined.

synthase other than TEAS can be used as the query

As exempli?ed by TEAS, terpene synthases of the present

sequence, e.g., regions of terpene synthases given in SEQ ID

invention can have a ?rst domain segment comprising

NOS: 4, 6, 8, 10, 12, 20, 22, 24, 26, 28, 30, 32, 34—40, 42,
44, 46, 48, 50, 52, 54, 56, or 58, that have signi?cant

helices A and C (an A-C loop), and a second domain

comprising helices I and K (a I-K loop) (FIG. 1). The
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ordering of these loops upon substrate binding results in a
closed, solvent-inaccessible active site pocket As the I-K
loop becomes ordered, a lid-type structure is formed that

terminus in taxadiene synthase (SEQ ID NO: 44) With
respect to TEAS, or are Within solvent-exposed loops in the

amino-terminal domain. Thus, regions of taxadiene synthase

clamps doWn over the active site entrance in the presence of

substrate and an extended aromatic patch deep Within the
active site pocket is formed. As the A-C loop becomes

60

ordered, it translates inWard toWard the active site, position
ing certain R groups in this loop at or near the active site.

Thus, substrate binding to the active site results in a change

in protein conformation.
To identify or create mutant terpene synthases, sequence
alignments can be performed to locate speci?c residues and

sequence identity to residues 265—535 of SEQ ID NO: 2. For
example, large sequence insertions are present at the amino
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With greater than 20% sequence identity to SEQ ID NO: 2
are closer to the carboxy-terminal end, e.g., from residue
579 to residue 847 of SEQ ID NO: 44.
Useful regions of other terpene synthases that can be used
as the query sequence include, Without limitation, residues
343 to 606 of SEQ ID NO: 20, 316 to 586 of SEQ ID NO:
22, residues 352 to 622 of SEQ ID NO: 58, residues 272 to
540 encoded by SEQ ID NO: 33, residues 319 to 571 of SEQ
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ID NO: 42, residues 579 to 847 of SEQ ID NO: 44, residues
495 to 767 of SEQ ID NO: 46, residues 295 to 564 of SEQ
ID NO: 48, residues 307 to 578 of SEQ ID NO: 50, residues
264 to 533 of SEQ ID NO: 52, residues 585 to 853 of SEQ
ID NO: 56, residues 307 to 574 of SEQ ID NO: 54, residues
309 to 577 of SEQ ID NO: 24, residues 315 to 584 of SEQ
ID NO: 26, residues 265 to 536 of SEQ ID NO: 28, residues
342 to 612 of SEQ ID NO: 30 and residues 273 to 541 of
SEQ ID NO: 32.
One or more of the speci?c residues in the subject
sequence that align With residues in the query sequence are

G+C content of many bacterial genes results in the genera

tion of sequences mimicking or duplicating plant gene
control sequences that are highly A+T rich. The presence of
A+T rich sequences Within the genes introduced into plants

(e.g., TATA box regions normally found in gene promoters)
may result in aberrant transcription of the gene(s). In
addition, the presence of other regulatory sequences residing

in the transcribed mRNA (e.g. polyadenylation signal
sequences (AAUAAA) or sequences complementary to
10

small nuclear RNAs involved in pre-mRNA splicing) may
lead to RNA instability. Therefore, one goal in the design of

mutated in the preselected polypeptide, e.g, by making

genes is to generate nucleic acid sequences that have a G+C

mutations in a nucleic acid encoding the polypeptide. The
mutant terpene synthase thus created can then be expressed
in a host cell and the protein evaluated for enZymatic

content that affords mRNA stability and translation accuracy

activity, if desired.
Mutant proteins of the present invention may be prepared

15

genetic code (i.e., some amino acids are speci?ed by more
than one codon), evolution of the genomes of different
organisms or classes of organisms has resulted in differential
usage of redundant codons. This “codon bias” is re?ected in

in a number of Ways including but not limited to

oligonucleotide-directed mutagenesis, deletion, chemical
mutagenesis, and the like. One or more R-groups associated
With the active site ot-carbon atoms in a terpene synthase are

for a particular expression system.
Due to the plasticity afforded by the redundancy of the

20

the mean base composition of protein coding regions. For
example, organisms With relatively loW G+C contents utiliZe

changed by altering the nucleotide sequence of the corre

codons having A or T in the third position of redundant

sponding gene. For example, a mutation can be introduced
into SEQ ID NO:1, the nucleotide sequence for TEAS, at
codons encoding one or more of the folloWing sixteen

codons, Whereas those having higher G+C contents utiliZe
codons having G or C in the third position. Therefore, in
25

ot-carbons: ot-carbon 1=Cys 270; ot-carbon 2=Trp 273;
ot-carbon 3=Ile 294; ot-carbon 4=Ile 297; ot-carbon
5=Ser298; ot-carbon 6=Thr 402; ot-carbon 7=Thr 403;
ot-carbon 8=Tyr 404; ot-carbon 9=Leu 407; ot-carbon

10=Cys 440; ot-carbon 11=Val 516; ot-carbon 12=Thr 519;
ot-carbon 13=Tyr 520; ot-carbon 14=Asp 525; ot-carbon

mined for genes of a particular organism deposited in
GenBank can provide this information. After determining
30

the bias thereof, the neW gene sequence can be analyZed for
restriction enZyme sites as Well as other sites that could

affect transcription such as exon:intron junctions, polyA
addition signals, or RNA polymerase termination signals.
Genes encoding synthases can be placed in an appropriate

15=Tyr 527; or ot-carbon 16=Thr 528. The protein encoded

by the mutant gene is then produced by expressing the gene
in, for example, a bacterial or plant expression system.
Alternatively, synthase mutants may be generated by site

reengineering genes for expression, one may Wish to deter
mine the codon bias of the organism in Which the gene is to
be expressed. Looking at the usage of the codons as deter
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vector, depending on the artisan’s interest, and can be

speci?c replacement of a particular amino acid With an

expressed using a suitable expression system. An expression

unnaturally occurring amino acid. As such, synthase mutants

vector, as is Well knoWn in the art, typically includes
elements that permit replication of said vector Within the

may be generated through replacement of an amino acid
residue or a particular cysteine or methionine residue With
selenocysteine or selenomethionine. This may be achieved

host cell and may contain one or more phenotypic markers
40

by groWing a host organism capable of expressing either the
Wild-type or mutant polypeptide on a groWth medium
depleted of natural cysteine or methionine or both and

groWing on medium enriched With either selenocysteine,
selenomethionine, or both. These and similar techniques are
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described in Sambrook et al., (Molecular Cloning, A Labo

ratory Manual, 2” Ed. (1989) Cold Spring Harbor Labora

tory Press).

a plant plastid (see US. Pat. Nos. 4,762,785; 5,451,513 and

Another suitable method of creating mutant synthases of
the present invention is based on a procedure described in
Noel and Tsal (1989) J. Cell. Biochem., 40:309—320. In so

for selection of cells containing said gene. The expression
vector Will typically contain sequences that control expres
sion such as promoter sequences, ribosome binding sites,
and translational initiation and termination sequences.
Expression vectors may also contain elements such as
subgenomic promoters, a repressor gene or various activator
genes. The artisan may also choose to include nucleic acid
sequences that result in secretion of the gene product,
movement of said product to a particular organelle such as

50

5,545,817), or other sequences that increase the ease of

peptide puri?cation, such as an af?nity tag.
AWide variety of expression control sequences are useful

doing, the nucleic acid encoding the synthase can be syn

thetically produced using oligonucleotides having overlap

in expressing mutated synthases When operably linked

ping regions, the oligonucleotides being degenerate at spe

thereto. Such expression control sequences include, for
example, the early and late promoters of SV40 for animal
cells, the lac system, the trp system, major operator and
promoter systems of phage )t, and the control regions of coat
proteins, particularly those from RNA viruses in plants. In E.

ci?c bases so that mutations are induced.
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According to the present invention, nucleic acid
sequences encoding a mutated synthase can be produced by
the methods described herein, or any alternative methods
available to the skilled artisan. In designing the nucleic acid

sequence (gene) of interest, it may be desirable to reengineer
the gene for improved expression in a particular expression
system. For example, it has been shoWn that many bacteri
ally derived genes do not express Well in plant systems. In

coli, a useful transcriptional control sequence is the T7 RNA
60

polymerase binding promoter, Which can be incorporated
into a pET vector as described by Studier et al., (1990)

Methods EnZymology, 185:60—89.
For expression, a desired gene should be operably linked
to the expression control sequence and maintain the appro

some cases, plant-derived genes do not express Well in
G+C content or A+T content of the gene relative to the

priate reading frame to permit production of the desired
synthase. Any of a Wide variety of Well-knoWn expression

expression system being used. For example, the very loW

vectors are of use in the present invention. These include, for

bacteria. This phenomenon may be due to the non-optimal
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example, vectors consisting of segments of chromosomal,

those derived from SV40, bacterial plasmids (including

In addition to numerous technologies for transforming
plants, the type of tissue that is contacted With the genes of
interest may vary as Well. Suitable tissue includes, but is not

those from E. coli such as col E1, pCR1, pBR322 and

limited to, embryogenic tissue, callus tissue, hypocotyl,

non-chromosomal and synthetic DNA sequences such as

derivatives thereof, pMB9), Wider host range plasmids such
as RP4, phage DNA such as phage )t, NM989, M13, and

meristern and the like. Almost all plant tissues may be

transformed during dedifferentiation using the appropriate
techniques described herein.

other such systems as described by Sambrook et al.,

(Molecular Cloning, A Laboratory Manual, 2”d Ed. (1989)
Cold Spring Harbor Laboratory Press).
A Wide variety of host cells are available for expressing
synthase mutants of the present invention. Such host cells
include, Without limitation, bacteria such as E. coli, Bacillus

Regardless of the transformation system used, a gene
encoding a mutant synthase is preferably incorporated into
10

sequence (plant promoter regulatory element). In addition to

and Streptomyces, fungi, yeast, animal cells, plant cells,
insect cells, and the like. Preferred embodiments of the
present invention include terpene synthase mutants that are
expressed in E. coli or in plant cells. Said plant cells can

plant promoter regulatory elements, promoter regulatory
elements from a variety of sources can be used ef?ciently in
15

either be in suspension culture or a culture on a solid support
such as an agar-based medium.

Genes encoding synthases of the present invention can
also be expressed in transgenic plant cells. In order to
produce transgenic plants, vectors containing a nucleic acid

mannopine synthase promoter may be used. Promoters of
20

25

identify transformed cells against a high background of

30

to the antibiotics kanamycin, neomycin, and G418, as Well
as those genes Which encode for resistance or tolerance to

Without undue experimentation and Without departing from

imidaZolinones, sulfonylureas, and triaZolophyrimidine
35

the like. In addition to a selectable marker gene, it may be
desirable to use a reporter gene. In some instances a reporter

the scope of this invention.
Once a synthase of the present invention is expressed, the
protein obtained therefrom can be puri?ed so that structural

40

analysis, modeling, and/or biochemical analysis can be
performed, as exempli?ed herein. The nature of the protein
obtained can be dependent on the expression system used.
For example, genes, When expressed in mammalian or other
eukaryotic cells, may contain latent signal sequences that
may result in glycosylation, phosphorylation, or other post
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function. Once the proteins are expressed, they can be easily
isolated and puri?ed using techniques common to the person

provided in K. Weising et al., 1988, Ann. Rev. Genetics,
22:421.

The genes are expressed either by promoters expressing in
all tissues at all times (constitutive promoters), by promoters

expressing in speci?c tissues (tissue-speci?c promoters),

It should be understood that not all expression vectors and
expression systems function in the same Way to express the
mutated gene sequences of the present invention. Neither do
all host cells function equally Well With the same expression
system. HoWever, one skilled in the art may make a selection

among these vectors, expression control sequences, and host

glyphosate, hygromycin, methotrexate, phosphinothricin,

gene may be used With a selectable marker. Reporter genes
alloW the detection of transformed cell and may be used at
the discretion of the artisan. A list of these reporter genes is

like. Numerous promoters are available to skilled artisans
for use at their discretion.

untransformed cells. Such selectable marker genes include
but are not limited to aminoglycoside phosphotransferase

herbicides, such as chlorosulfuron, bromoxynil, dalapon and

viral origin, such as the cauli?ower mosaic virus (35S and
19S) are also desirable. Plant promoter regulatory elements
also include, but are not limited to, ribulose-1,6

bisphosphate carboxylase small subunit promoter, beta
conglycinin promoter, phaseolin promoter, ADH promoter,
heat-shock promoters, and tissue speci?c promoters and the

selectable marker gene. A selectable marker gene is used to

gene of transposon Tn5 (Aph II) Which encodes resistance

plant cells to express foreign genes. For example, promoter
regulatory elements of bacterial origin, such as the octopine

synthase promoter, the nopaline synthase promoter, the

construct encoding a mutant terpene synthase are inserted

into the plant genome. Preferably, these recombinant vectors
are capable of stable integration into the plant genome. One
variable in making a transgenic plant is the choice of a

a gene transfer vector adapted to express said gene in a plant

cell by including in the vector an expression control

translational modi?cations, Which may or may not alter

promoters expressing at speci?c stages of development

(developmental promoters), and/or promoter expression in

having ordinary skill in the art of protein biochemistry and

response to a stimulus or stimuli (inducible promoters). The
choice of these is at the discretion of the artisan.

Protein Science, Chanda, V. B., Ed., John Wiley & Sons, Inc.

Several techniques exist for introducing foreign genes
into plant cells, and for obtaining plants that stably maintain

as described in Colligan et al., (1997) Current Protocols in
50

Such techniques often include the use of cation-exchange or

anion-exchange chromatography, gel ?ltration-siZe exclu
sion chromatography, and the like. Another technique that

and express the introduced gene. Such techniques include
acceleration of genetic material coated directly into cells
(US. Pat. No. 4,945,050). Plant may also be transformed

may be commonly used is affinity chromatography. Affinity
chromatography can include the use of antibodies, substrate

using Agrobacterium technology (US. Pat. Nos. 5,177,010,
5,104,310, 5,149,645, 5,469,976, 5,464,763, 4,940,838,
4,693,976, 5,591,616, 5,231,019, 5,463,174, 4,762,785,
5,004,863, and 5,159,135; European Patent Applications
116718, 290799, 320500, 604662, 627752, 0267159, and
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0292435. Other transformation technologies include Whis
kers technology, see US. Pat. Nos. 5,302,523 and 5,464,
765. Electroporation technology has also been used to
transform plants, see WO 87/06614, WO 92/09696 and WO
93/21335 and US. Pat. Nos. 5,472,869 and 5,384,253. Viral
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analogs, or histidine residues (His-tag technology).
Once puri?ed, mutants of the present invention may be
characteriZed by any of several different properties. For
example, such mutants may have altered active site surface
charges of one or more charge units. In addition, the mutants
may have an altered substrate speci?city or spectrum of

reaction product relative to a non-mutated synthase.
The present invention alloWs for the characteriZation of

mutant terpene synthase by crystalliZation folloWed by
X-ray diffraction. Polypeptide crystalliZation occurs in solu

vector expression systems can also be used such as those 65 tions Where the polypeptide concentration exceeds it solu

described in US. Pat. Nos. 5,316,931, 5,589,367, 5,811,653,
and 5,866,785.

bility maximum (i.e., the polypeptide solution is
supersaturated). Such solutions may be restored to equilib
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rium by reducing the polypeptide concentration, preferably
through precipitation of the polypeptide crystals. Often

protein may facilitate production of crystalline protein
samples. Removal of such segments can be done using
molecular biology techniques or treatment of the protein
With proteases such as trypsin, chymotrypsin, subtilisin.

polypeptides may be induced to crystalliZe from supersatu
rated solutions by adding agents that alter the polypeptide
surface charges or perturb the interaction betWeen the

Such procedures can result in the removal of ?exible

polypeptide segments that may negatively affect crystalli

polypeptide and bulk Water to promote associations that lead

Zation.
The crystals so produced have a Wide range of uses. For

to crystalliZation.
Compounds knoWn as “precipitants” are often used to

example, high quality crystals are suitable for X-ray or

decrease the solubility of the polypeptide in a concentrated

solution by forming an energetically unfavorable precipitat

10

ing depleted layer around the polypeptide molecules (Weber,
1991, Advances in Protein Chemistry, 41:1—36). In addition

serve as a further puri?cation method. In some instances, a

to precipitants, other materials are sometimes added to the

polypeptide crystalliZation solution. These include buffers to
adjust the pH of the solution and salts to reduce the solubility

polypeptide or protein Will crystalliZe from a heterogeneous
15

of the polypeptide. Various precipitants are knoWn in the art

supersaturation, the vessel is sealed and set aside until

20

Because synthases may crystalliZe in more than one
crystal form, the structural coordinates of ot-carbons of an
active site determined from a synthase or portions thereof, as
25

retained in a sealed dialysis membrane that is placed into a

solution containing precipitant. Equilibration across the
30

saturation levels.

In the preferred hanging drop technique (McPherson,
1976, J. Biol. Chem., 6300—6306), an initial polypeptide
mixture is created by adding a precipitant to a concentrated

35

Whether it is another crystal form of a synthase, a synthase
having a mutated active site, or the crystal of some other

polypeptide does not crystalliZe. Asmall drop of this mixture

protein With signi?cant sequence identity and/or structural
40

tion of precipitant or other dehydrating agent. The difference
in the precipitant concentrations causes the protein solution
to have a higher vapor pressure than the solution. Since the

system containing the tWo solutions is sealed, an equilibrium
is established, and Water from the polypeptide mixture
transfers to the second solution. This equilibrium increases
the polypeptide and precipitant concentration in the
polypeptide solution. At the critical concentration of
polypeptide and precipitant, a crystal of the polypeptide may
form.
Another method of crystalliZation introduces a nucleation
site into a concentrated polypeptide solution. Generally, a
concentrated polypeptide solution is prepared and a seed

crystal of the polypeptide is introduced into this solution. If
the concentration of the polypeptide and any precipitants are
correct, the seed crystal Will provide a nucleation site around

homology of a synthase may be determined using the
coordinates given in Tables 10 and/or 11. This method
provides suf?cient structural form for the unknoWn crystal
more efficiently than attempting to determine such informa
tion ab initio. In addition, this method can be used to
determine Whether or not a given synthase in question falls
Within the scope of this invention.
As further disclosed herein, synthases and mutants thereof
may be crystalliZed in the presence or absence of substrates
and substrate analogs. The crystal structures of a series of
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complexes may then be solved by molecular replacement
and compared to that of the Wild-type to assist in determi
nation of suitable replacements for R-groups Within the
active site, thus making synthase mutants according to the
present invention.
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All mutants of the present inventions may be modeled

using the information disclosed herein Without necessarily
having to crystalliZe and solve the structure for each and

Which larger crystal forms. In preferred embodiments, the

every mutant. For example, one skilled in the art may use

crystals of the present invention are formed in hanging drops
With 15% PEG 8000; 200 mM magnesium acetate or mag

yet having R-groups that may or may not be identical.
Furthermore, the structural coordinates disclosed herein may
be used to determine the structure of the crystalline form of
other proteins With signi?cant amino acid or structural
homology to any functional domain of a synthase. One
method that may be employed for such purpose is molecular

replacement. In this method, the unknoWn crystal structure,

and precipitants are such that in this initial form, the
is placed on a glass slide that is inverted and suspended over
a reservoir of a second solution. The system is then sealed.
Typically, the second solution contains a higher concentra

provided by this invention, are particularly useful to solve
the structure of other crystal forms of synthases. The struc
tural coordinates, as provided herein, may also be used to
solve the structure of synthases having ot-carbons position
Within the active sites in a manner similar to the Wild-type

membrane increases the polypeptide and precipitant con

polypeptide solution. The concentrations of the polypeptide

formulated to provide an aqueous solution having other uses
as desired.

crystals appear. In the dialysis method, polypeptide is

centrations thereby causing the polypeptide to reach super

centrifugation, etc., folloWed by redissolving the polypep
high-quality crystals needed for diffraction studies. The
high-quality crystals may also be dissolved in Water and then

and many of the polyglycols, such as polyethylene glycol.

initiation, and dialysis. In each of these methods, it is
important to promote continued crystalliZation after nucle
ation by maintaining a supersaturated solution. In the batch
method, polypeptide is mixed With precipitants to achieve

mixture into crystals. Isolation of such crystals by ?ltration,
tide affords a puri?ed solution suitable for use in groWing the

and include the folloWing: ethanol, 3-ethyl-2-4 pentanediol,

Commonly used polypeptide crystalliZation methods
include the folloWing techniques: batch, hanging drop, seed

neutron diffraction analysis to determine the three
dimensional structure of a mutant synthase and to design
additional mutants thereof. In addition, crystalliZation can

one of several specialiZed computer programs to assist in the
60

nesium chloride, 100 mM 3-(N-morpholino)-2
hydroxypropanesulfonic acid (pH 7.0), 1 mM dithiothreitol

process of designing synthases having mutated active sites.
Examples of such programs can be as folloWs: GRID

artisan to induce crystalliZation. The removal of polypeptide

(Goodford, 1985, J. Med. Chem., 28:849—857); MCSS
(Miranker and Karplus, 1991, Proteins: Structure, Function
and Genetics, 11:29—34); AUTODOCK (Goodsell and
Olsen, 1990, Proteins: Structure, Function, and Genetics,
8:195—202); and DOCK (KuntZ et al., 1982, J. Mol. Biol.,

segments at the amino or carboxyl terminal end of the

161:269—288). In addition, speci?c computer programs are

as precipitant.

Some proteins may be recalcitrant to crystalliZation.
HoWever, several techniques are available to the skilled
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